Join Insight Molecular Diagnostics (iMDx) for a virtual key opinion leader (KOL) event featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company’s GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA results for transplanted organ health monitoring.

The event will provide an overview of GraftAssure, currently under review by the FDA to be commercialized in kitted form for labs to test patients for kidney transplant rejection. Dr. Liebo will discuss how a kitted GraftAssure test (GraftAssureDx) can be used for in-house heart transplant rejection monitoring, as well as implications for the industry and patients.

A live question and answer session will follow.